Free Trial

Myriad Genetics (MYGN) News Today

→ It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad)
Free MYGN Stock Alerts
$21.54
-0.60 (-2.71%)
(As of 02:14 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 8 at 5:50 AM | marketbeat.com
Rafferty Asset Management LLC Reduces Position in Myriad Genetics, Inc. (NASDAQ:MYGN)
Rafferty Asset Management LLC trimmed its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 17.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 171,399 shares of the company's stock aft
June 8 at 2:12 AM | americanbankingnews.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $24.88 Average PT from Analysts
June 6, 2024 | insidertrades.com
Daniel K. Spiegelman Sells 3,788 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) Stock
June 5, 2024 | marketbeat.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have earned an average recommendation of "Hold" from the nine research firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five
June 5, 2024 | americanbankingnews.com
Jefferies Financial Group Reiterates "Underperform" Rating for Myriad Genetics (NASDAQ:MYGN)
June 4, 2024 | marketbeat.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Director Sells $83,487.52 in Stock
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director Daniel K. Spiegelman sold 3,788 shares of Myriad Genetics stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $22.04, for a total value of $83,487.52. Following the transaction, the director now directly owns 36,705 shares in the company, valued at approximately $808,978.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
June 3, 2024 | globenewswire.com
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 3, 2024 | marketbeat.com
Pura Vida Investments LLC Purchases Shares of 50,000 Myriad Genetics, Inc. (NASDAQ:MYGN)
Pura Vida Investments LLC acquired a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company's stock, valued at approxima
June 3, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Shares Gap Down to $22.76
Myriad Genetics (NASDAQ:MYGN) Shares Gap Down to $22.76
June 3, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Given Underperform Rating at Jefferies Financial Group
Jefferies Financial Group reaffirmed an "underperform" rating and set a $20.00 price objective (down previously from $25.00) on shares of Myriad Genetics in a research report on Monday.
May 30, 2024 | globenewswire.com
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 29, 2024 | marketbeat.com
Monashee Investment Management LLC Invests $957,000 in Myriad Genetics, Inc. (NASDAQ:MYGN)
Monashee Investment Management LLC bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approx
May 27, 2024 | marketbeat.com
Charles Schwab Investment Management Inc. Has $17.73 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)
Charles Schwab Investment Management Inc. boosted its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 926,159 shares of the company's stock after buying an additional
May 26, 2024 | marketbeat.com
BNP Paribas Financial Markets Has $1.72 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)
BNP Paribas Financial Markets lifted its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 115.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 90,009 shares of the company's stock after buy
May 25, 2024 | marketbeat.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Jump Financial LLC
Jump Financial LLC trimmed its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 77.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,047 shares of the company's stock after selling 65,877 s
May 23, 2024 | ca.finance.yahoo.com
MYGN Aug 2024 33.000 call
May 23, 2024 | globenewswire.com
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024 | ca.finance.yahoo.com
MYGN Jun 2024 22.000 put
May 17, 2024 | insidertrades.com
Paul J. Diaz Sells 57,844 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) Stock
May 16, 2024 | globenewswire.com
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16, 2024 | insidertrades.com
Lee Nisley Newcomer Sells 6,200 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) Stock
May 16, 2024 | finance.yahoo.com
Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)
May 16, 2024 | finance.yahoo.com
Insider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)
May 13, 2024 | marketbeat.com
Piper Sandler Boosts Myriad Genetics (NASDAQ:MYGN) Price Target to $28.00
Piper Sandler raised their price objective on Myriad Genetics from $23.00 to $28.00 and gave the company a "neutral" rating in a report on Monday.
May 12, 2024 | marketbeat.com
Natixis Advisors L.P. Increases Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)
Natixis Advisors L.P. boosted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 44.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,278 shares of the company's stock after purchasin
May 11, 2024 | finance.yahoo.com
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
May 9, 2024 | msn.com
Leerink Partners Upgrades Myriad Genetics (MYGN)
May 9, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Reaches New 1-Year High at $24.92
Myriad Genetics (NASDAQ:MYGN) Hits New 1-Year High at $24.92
May 9, 2024 | finance.yahoo.com
Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
May 8, 2024 | marketwatch.com
Myriad Genetics Shares Rise 15% After 1Q Revenue Beats Estimates
May 8, 2024 | finance.yahoo.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
May 8, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Shares Gap Up Following Strong Earnings
Myriad Genetics (NASDAQ:MYGN) Shares Gap Up After Strong Earnings
May 8, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Lifted to "Outperform" at SVB Leerink
SVB Leerink raised Myriad Genetics from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $25.00 to $35.00 in a report on Wednesday.
May 8, 2024 | finance.yahoo.com
Myriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ...
May 8, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings Guidance
Myriad Genetics (NASDAQ:MYGN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.000-0.050 for the period, compared to the consensus estimate of 0.020. The company also issued revenue guidance of $820.0 millionillion-$840.0 millionillion, compared to the consensus estimate of $826.6 millionillion.
May 7, 2024 | investorplace.com
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024
May 7, 2024 | uk.finance.yahoo.com
Myriad Genetics Reports Q1 2024 Earnings: Revenue Growth Surpasses Estimates Amidst Challenges
May 7, 2024 | markets.businessinsider.com
Myriad Genetics Inc. Q1 Loss Decreases, beats estimates
May 7, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS
Myriad Genetics (NASDAQ:MYGN - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.09. Myriad Genetics had a negative net margin of 34.96% and a negative return on equity of 8.03%. The firm had revenue of $202.20 million for the quarter, compared to analyst estimates of $193.51 million. During the same period last year, the business earned ($0.28) EPS. Myriad Genetics's revenue for the quarter was up 11.6% compared to the same quarter last year.
May 7, 2024 | marketbeat.com
Myriad Genetics (NASDAQ:MYGN) Issues FY24 Earnings Guidance
Myriad Genetics (NASDAQ:MYGN) updated its FY24 earnings guidance. The company provided EPS guidance of $0.00 to $0.05 for the period, compared to the consensus estimate of $0.03.
May 7, 2024 | msn.com
Myriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.2M beats by $8.95M
May 7, 2024 | globenewswire.com
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 7, 2024 | finanznachrichten.de
Myriad Genetics, Inc.: Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 7, 2024 | globenewswire.com
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 7, 2024 | finance.yahoo.com
Myriad Genetics (NASDAQ:MYGN) shareholders have endured a 26% loss from investing in the stock five years ago
May 7, 2024 | markets.businessinsider.com
Myriad Genetics earnings preview: what Wall Street is expecting
May 6, 2024 | seekingalpha.com
Myriad Genetics Q1 2024 Earnings Preview
May 2, 2024 | finance.yahoo.com
YourBio Health Congratulates Myriad Genetics on One Million Sales of SneakPeek® Tests Enabled by YourBio's Virtually Painless TAP Technology
May 1, 2024 | marketbeat.com
Myriad Genetics (MYGN) Scheduled to Post Quarterly Earnings on Tuesday
Myriad Genetics (NASDAQ:MYGN) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports.
April 30, 2024 | finance.yahoo.com
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
Get Myriad Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit Strategy (Ad)

The crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially profit from this trillion-dollar niche WITHOUT buying a single coin, NFT or investing in ANYTHING.

Grab the PDF here for free:

MYGN Media Mentions By Week

MYGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MYGN
News Sentiment
▼
0.60

0.76
▲
Average
Medical
News Sentiment

MYGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MYGN Articles
This Week
▼
12

4
▲
MYGN Articles
Average Week

Get Myriad Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:MYGN) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit Strategy
The crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...
DeFi Distribution | Sponsored
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Hurry! Buy this stock before the Robinhood traders do!
Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...
Traders Agency | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Moonshot Coins for the Current Crypto Run
Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...
Crypto 101 Media | Sponsored